Laddar populära aktier...
Qlife Holding AB (publ) (“Qlife” or the “Company”) announces that members of the Company's Board of Directors and management, including CEO ...
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Transition to a commercial business
The CEO of Qlife Thomas Warthoe has been sanctioned by Finansinspektionen related to insider information.
Qlife has been in discussions with a top-20 global Pharma company to explore opportunities for the sales, distribution, and marketing of the...
The company is pleased to announce that Qlife, in collaboration with its strategic partner Hipro Biotechnology, has developed a new Egoo Hea...
Qlife provides sales and regulatory updates
Qlife provides update on operational progress in China
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, ...
Vid årsstämman den 26 juni 2024 valdes Göteborgs Revision Kommanditbolag (”Göteborgs Revision”) till revisionsbolag för Qlife Holding AB (pu...
Qlife announces outcome in directed issues
Idag, den 8 november 2024, hölls extra bolagsstämma, tillika den andra kontrollstämman, i Qlife Holding AB.
Today, on 8 November 2024, an extraordinary general meeting, and the second control meeting, was held in Qlife Holding AB.
Finally there
Aktieägarna i Qlife Holding AB, org.nr 559224-8040 (”Bolaget”), kallas till extra bolagsstämma, tillika andra kontrollstämma, den 8 november...
Qlife Holding AB (publ) (“Qlife” or the “Company”) has decided to withdraw its proposal to change the Company’s name as the intended name, E...
Resent due to technical problems news distributor. Since its inception, Qlife has been developing the Phenylalanine (PHE) test capsule and ...
Since its inception, Qlife has been developing the Phenylalanine (PHE) test capsule and is now prepared to offer it for sale to individuals ...
Peter Warthoe, one of the three founders of Qlife, is back in his management role as Chief Scientific Officer and will focus on the company’...
Qlife Holding AB (publ) (“Qlife” or the “Company”) has, in accordance with Chapter 25, Section 16 of the Swedish Companies Act (“ABL”), prep...
Qlife Holding AB (publ) (“Qlife” or the “Company”) recently announced a restructuring and new financing to support its strategic goals.
Qlife Holding AB (publ) ("Qlife" or the "Company") is pleased to announce a comprehensive business update in light of recent strategic devel...
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, NEW ZEALA...
Restructuring the company
Med anledning av sammanläggningen av aktier i Qlife Holding AB (publ) (”Qlife” eller ”Bolaget”) som beslutades på årsstämman den 26 juni 202...
Qlife Holding AB ("Qlife" or the "Company") has today received information that Qlife ApS’s reconstructor will terminate the corporate restr...
Styrelsen i Qlife Holding AB (publ) (”Qlife” eller ”Bolaget”) har, med stöd av bemyndigandet från årsstämman som hölls den 26 juni 2024, bes...
Qlife has participated a research trial at Emory University (USA) focused on young women living with PKU (phenylketonuria) and made Egoo sys...
Kommuniké från årsstämma 2024 i Qlife Holding AB
Qlife Holding AB loses arbitration proceedings against Aidian
Qlife Holding AB publishes information by reason of ongoing negotiations with Atlas Special Opportunities, LLC, regarding a financing soluti...
The exercise period for warrants series TO 4 that were issued in conjunction with Qlife Holding AB's ("Qlife" or the "Company") rights issue...
Qlife Holding AB’s (“Qlife”) annual report has been published on Qlife’s website as of today, https://qlifeholding.
Qlife Holding AB:s (“Qlife”) årsredovisning finns från och med idag tillgänglig på Qlifes hemsida, https://qlifeholding.
Qlife and its partner Hipro Biotechnology have validated performance of the first biomarker C-Reactive Protein and are now starting clinical...
Standing firm and moving forward
Aktieägarna i Qlife Holding AB, org.nr 559224-8040, kallas till årsstämma den 26 juni 2024 kl.
Qlife Holding AB (“Qlife” or the “Company”) has today entered into an addendum with the holders of the Company’s outstanding convertible deb...
Today, on 23 April 2024, an extraordinary general meeting, and the first meeting for liquidation purposes, was held in Qlife Holding AB.
CORRRECTION, previous version should have had a MAR-legend, below corrected.
Under Danish law the company can during a reconstrution phase resolve on creditor issues and access certain loans.
UPDATE: Qlife is emphasizing its strategy to finalize regulatory and Go-To-Market in China, register in Asian countries through partners, an...
Qlife signs letter of intent with South Korean company Precision Biosensor as part of B2B strategy to enter major markets with Egoo Health, ...
Notice of extraordinary general meeting, and the first meeting for liquidation purposes, in Qlife Holding AB
UPDATE: Qlife is emphasizing that the call today for an extraordinary general meeting (EGM) is a necessity according to Swedish law, but tha...
The board of directors of Qlife Holding AB ("Qlife" or the "Company"), has, in accordance with Chapter 25, Section 13 of the Swedish Compani...
On 12 December 2023, Qlife Holding AB (“Qlife” or the “Company”) announced a rights issue of units of approximately SEK 49.
Monday, February 26, 2024, is the last day of the subscription period in Qlife Holding AB’s (“Qlife” or the “Company”) rights issue of units...
Qlife announces that its core patent for the Egoo system has been granted in the EU and other countries in the European market, as well as i...
UPDATE: Qlife has previously reported the potential of its Chinese collaboration and is now updating accordingly: Qlife’s collaboration with...
